Combined influence of adjuvant therapy and interval after surgery on peripheral CD4+ T lymphocytes in patients with esophageal squamous cell carcinoma

Ling,Yang; Fan,Lieying; Dong,Chunlei; Zhu,Jing; Liu,Yongping; Ni,Yan; Zhu,Changtai; Zhang,Changsong

doi:10.3892/etm_00000020

Combined influence of adjuvant therapy and interval after surgery on peripheral CD4+ T lymphocytes in patients with esophageal squamous cell carcinoma

Authors:
- Yang Ling
- Lieying Fan
- Chunlei Dong
- Jing Zhu
- Yongping Liu
- Yan Ni
- Changtai Zhu
- Changsong Zhang
View Affiliations

Affiliations: Laboratory of Clinical Oncology, Changzhou Tumor Hospital, Medical College of Soochow University, Jiangsu, P.R. China
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000020
Pages: 113-120

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate possible differences in cellular immunity between chemo- and/or radiotherapy groups during a long interval after surgery in esophageal squamous cell carcinoma (ESCC) patients. Cellular immunity was assessed as peripheral lymphocyte subsets in response to chemotherapy (CT), radiotherapy (RT) and CT+RT by flow cytometric analysis. There were 139 blood samples obtained at different time points relative to surgery from 73 patients with ESCC. The changes in the absolute and relative proportions of lymphocyte phenotypes were significant among the adjuvant therapy groups. There were significant differences in the absolute counts of CD4+ and CD8+ T cells among the interval groups, and a lower CD4/CD8 ratio was found in patients following a prolonged interval. RT alone had a profound effect on the absolute counts of CD3+, CD4+ and CD8+ T cells compared with the other groups. CD4+ T cells exhibited a decreasing trend during a long interval, leading to a prolonged T-cell imbalance after surgery. Univariate analysis revealed that the interaction of the type of adjuvant therapy and the interval after surgery was correlated only with the percentage of CD4+ T cells. The percentage of CD4+ T cells can be used as an indicator of the cellular immunity after surgery in ESCC patients. However, natural killer cells consistently remained suppressed in ESCC patients following adjuvant therapy after surgery. These findings confirm an interaction between adjuvant therapy and the interval after surgery on peripheral CD4+ T cells, and implies that adjuvant therapy may have selective influence on the cellular immunity of ESCC patients after surgery.

View Figures

View References

1.	Koebel CM, Vermi W, Swann JB, et al: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450:903–907. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Kim R, Emi M and Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology. 121:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Disis ML and Lyerly HK: Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol. 23:8923–8925. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Knutson KL and Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 54:721–728. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Ohlen C, Kalos M, Hong DJ, Shur AC and Greenberg PD: Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J Immunol. 166:2863–2870. 2001.PubMed/NCBI
6.	Lin DC, Du XL and Wang MR: Protein alterations in ESCC and clinical implications: a review. Dis Esophagus. 22:9–20. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Kang DH, Weaver MT, Park NJ, Smith B, McArdle T and Carpenter J: Significant impairment in immune recovery after cancer treatment. Nurs Res. 58:105–114. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Kleinberg L and Forastiere AA: Chemoradiation in the management of esophageal cancer. J Clin Oncol. 25:4110–4117. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Westerterp M, Boermeester MA, Omloo JM, et al: Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus. Cancer Immunol Immunother. 57:1837–1847. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Formenti SC and Demaria S: Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol. 26:1562–1563. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Emens LA and Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65:8059–8064. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Heidecke CD, Weighardt H, Feith M, et al: Neoadjuvant treatment of esophageal cancer: immunosuppression following combined radiochemotherapy. Surgery. 132:495–501. 2002. View Article : Google Scholar
14.	Van Sandick JW, Boermeester MA, Gisbertz SS, et al: Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome. Cancer Immunol Immunother. 52:617–624. 2003.PubMed/NCBI
15.	Mafune K and Tanaka Y: Influence of multimodality therapy on the cellular immunity of patients with esophageal cancer. Ann Surg Oncol. 7:609–616. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Cho Y, Miyamoto M, Kato K, et al: CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 63:1555–1559. 2003.
17.	Van der Most RG, Currie A, Robinson BW and Lake RA: Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res. 66:601–604. 2006.PubMed/NCBI
18.	Appay V, van Lier RA, Sallusto F and Roederer M: Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry. A73:975–983. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Lindemalm C, Mozaffari F, Choudhury A, et al: Immune response, depression and fatigue in relation to support intervention in mammary cancer patients. Support Care Cancer. 16:57–65. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Union Internationale Contre le Cancer: TNM Classification of Malignant Tumours. 6th edition. Wiley-Liss; New York: 2002
21.	Fagnoni FF, Lozza L, Zibera C, et al: T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology. 106:27–37. 2002.PubMed/NCBI
22.	Shiku H: Importance of CD4+ helper T-cells in antitumor immunity. Int J Hematol. 77:435–438. 2003.
23.	Ostrand-Rosenberg S: CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 23:413–419. 2005.
24.	Pardoll DM and Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 10:588–594. 1998.
25.	Velders MP, Markiewicz MA, Eiben GL and Kast WM: CD4+ T cell matters in tumor immunity. Int Rev Immunol. 22:113–140. 2003.
26.	Hakim FT, Cepeda R, Kaimei S, et al: Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 90:3789–3798. 1997.PubMed/NCBI
27.	Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S: Functions of natural killer cells. Nat Immunol. 9:503–510. 2008. View Article : Google Scholar
28.	Sinkovics JG and Horvath JC: Human natural killer cells: A comprehensive review. Int J Oncol. 27:5–47. 2005.PubMed/NCBI